These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33516752)

  • 1. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE).
    Ambrosy AP; Malik UI; Thomas RC; Parikh RV; Tan TC; Goh CH; Selby VN; Solomon MD; Avula HR; Fitzpatrick JK; Skarbinski J; Philip S; Granowitz C; Bhatt DL; Go AS
    Am Heart J; 2021 May; 235():54-64. PubMed ID: 33516752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
    Trivedi K; Le V; Nelson JR
    Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
    Bazarbashi N; Miller M
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
    J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
    Budoff MJ; Bhatt DL; Kinninger A; Lakshmanan S; Muhlestein JB; Le VT; May HT; Shaikh K; Shekar C; Roy SK; Tayek J; Nelson JR
    Eur Heart J; 2020 Oct; 41(40):3925-3932. PubMed ID: 32860032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
    Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
    Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.
    Bakbak E; Krishnaraj A; Bhatt DL; Quan A; Park B; Bakbak AI; Bari B; Terenzi KA; Pan Y; Fry EJ; Terenzi DC; Puar P; Khan TS; Rotstein OD; Mazer CD; Leiter LA; Teoh H; Hess DA; Verma S
    Med; 2024 Jul; 5(7):718-734.e4. PubMed ID: 38552629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
    Budoff MJ; Muhlestein JB; Bhatt DL; Le Pa VT; May HT; Shaikh K; Shekar C; Kinninger A; Lakshmanan S; Roy SK; Tayek J; Nelson JR
    Cardiovasc Res; 2021 Mar; 117(4):1070-1077. PubMed ID: 32609331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment.
    Weintraub WS; Bhatt DL; Zhang Z; Dolman S; Boden WE; Bress AP; King JB; Bellows BK; Tajeu GS; Derington CG; Johnson J; Andrade K; Steg PG; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Kolm P
    JAMA Netw Open; 2022 Feb; 5(2):e2148172. PubMed ID: 35157055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    Circulation; 2021 Jan; 143(1):33-44. PubMed ID: 33148016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
    Boden WE; Baum S; Toth PP; Fazio S; Bhatt DL
    Future Cardiol; 2021 Jan; 17(1):155-174. PubMed ID: 32959713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
    Crandell JR; Tartaglia C; Tartaglia J
    Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
    Boden WE; Bhatt DL; Toth PP; Ray KK; Chapman MJ; Lüscher TF
    Eur Heart J; 2020 Jun; 41(24):2304-2312. PubMed ID: 31872245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
    Maki KC; Dicklin MR
    Curr Opin Cardiol; 2020 Jul; 35(4):417-422. PubMed ID: 32412960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
    Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
    Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk.
    Dixon DL
    Am J Med; 2020 Jul; 133(7):802-804. PubMed ID: 32243872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.